An interventional study of fulvic acid and fulvic acid in Metabolic Syndrome, sponsored by Arizona State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Arizona State University · Not applicable, Interventional, and Other
Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements. Our preclinical studies have found that a soil derived organic mineral complex rich in fulvic acid prevented the high fat diet induced hyperglycemia, endothelial dysfunction, liver injury, endotoxemia, and gut dysbiosis induced by high-fat feeding in rats. We propose to examine the efficacy of fulvic acid (both 50 mg and 100 mg daily for 12 weeks) in the mitigation of symptoms related to metabolic syndrome.
Clinical trials examining the efficacy of fulvic acid on health parameters are scarce. However, shilajit, a natural substance rich in fulvic acid, was shown to reduce triglycerides, cholesterol, and increase HDL cholesterol as well as antioxidant status in healthy college students (n=30) after 45 days of supplementation (2 g daily). However, this quasi-experimental trial did not randomize participants into experimental groups, and causality cannot be evaluated. A 2018 review of the peer-reviewed literature on the therapeutic potential of fulvic acid concluded that although the available research is minimal, there was 'substantial evidence' to pursue fulvic acid research for improving biomarkers linked to chronic inflammatory diseases.
2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 1,572 interventional studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →Arizona State University is the lead sponsor of 238 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
50 mg
Dietary Supplement: fulvic acid
100 mg
Dietary Supplement: fulvic acid
cornstarch
Other: Placebo
50 mg
100 mg
cornstarch
girth
waist circumference in cm
Time frame: from enrollment to 6 week and to 12 week
hypertension
diastolic and systolic blood pressure
Time frame: from enrollment to 6 week and to 12 week
hyperglycemia
fasting blood glucose
Time frame: from enrollment to 6 week and to 12 week
hypertriglyceridemia
fasting blood triglycerides
Time frame: from enrollment to 6 week and to 12 week
cholesterol
fasting blood HDL cholesterol
Time frame: from enrollment to 6 week and to 12 week
Plan to share: No — There is no IPD.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 625 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 675 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.